RxDoctor Payments Data

Howard Elkin

Cardiovascular Disease · Whittier, CANPI 1821022864

Payments from drug & device makers

$5,114in general payments, 2019–2025

Across 208 payments — averaging $24.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$741
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$719
  • Novartis$655
  • E.r. Squibb & Sons, L.L.C.$563
  • Boehringer Ingelheim$348
  • Boston Scientific$305
  • plus $2K from 18 others

What the payments were for

  • Food & beverage$5,06399%
  • Education$511%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,114 in reported general payments places this provider in the 60th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$131,671
Medicare patients
256
Services billed
1,684

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban76$75,179
Repatha SureclickEvolocumab69$54,833
OzempicSemaglutide44$52,269
Praluent PenAlirocumab44$23,426
BrilintaTicagrelor45$22,632
EntrestoSacubitril/Valsartan16$17,581
Testosterone30$16,170
FarxigaDapagliflozin Propanediol14$12,013
Repatha SyringeEvolocumab26$8,750
Amlodipine-ValsartanAmlodipine Besylate/Valsartan35$2,140
Ezetimibe55$2,037
Nebivolol Hcl21$1,796
Valsartan39$1,243
Rosuvastatin Calcium108$1,187
Fenofibrate17$1,062

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$103$75,17976 claims
Novo NordiskOzempic$113$52,26944 claims
AstraZenecaBrilinta, Farxiga$87$34,64559 claims
NovartisEntresto$655$17,58116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Whittier

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →